ASH 2018 | Anti-KIR3DL2 mAb in refractory Sézary syndrome: IPH4102
Martine Bagot
• 18 Jan 2019
Sézary syndrome (SS), the most aggressive form of cutaneous T-cell lymphoma (CTCL), is characterized by a high expression of the KIR3DL2 receptor. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Martine Bagot, MD, PhD, of the Saint Louis Hospital, Paris, France, introduces the IPH4102-101 study (NCT02593045) assessing IPH4102, a first-in-class monoclonal antibody that targets KIR3DL2. Prof. Bagot reveals that IPH4102 is highly effective in patients with refractory SS, inducing meaningful clinical activity; making it an encouraging treatment option for these patients.
